Immunic Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Immunic, Inc. (IMUX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-100.51-93.61-120.41-92.95-44.02-34.93
Depreciation & Amortization0.130.110.080.090.040.05
Stock Based Compensation8.537.107.935.952.750.00
Change in Working Capital0.5615.059.53-9.28-2.37-1.36
Change in Accounts Payable3.150.820.800.181.000.00
Change in Other Working Capital-2.5814.238.738.63-3.370.00
Other Operating Activities1.727.104.768.632.758.05
Net Cash from Operating Activities-84.77-70.83-65.14-83.23-46.12-28.55
Investing Activities
Capital Expenditures-0.260.33-0.11-0.070.150.13
Purchases of Investments0.009.80-9.630.000.000.00
Sales/Maturities of Investments0.009.80-9.630.000.008.15
Other Investing Activities0.000.000.000.000.008.15
Net Cash from Investing Activities-0.269.46-9.74-0.07-0.1510.54
Financing Activities
Debt Repayment74.270.000.000.000.000.00
Common Stock Issued0.271.0399.7742.75154.565.20
Other Financing Activities-0.010.00-4.01-3.00-10.13-0.27
Net Cash from Financing Activities74.541.0395.7642.84144.43-0.27
Summary
Effect of Forex Changes on Cash-0.520.26-0.99-0.13-0.08-0.59
Net Change in Cash-11.01-60.3319.88-40.4698.08-18.28
Cash at Beginning of Period46.67106.7586.86127.4529.3713.07
Cash at End of Period35.6746.67106.7586.8629.37-5.80
Free Cash Flow-85.03-71.16-65.26-83.30-46.27-26.16